Agendia, Inc. to present new research on AI-driven digital pathology at ESMO 2026. The company focuses on precision oncology in breast cancer. The research will be presented as a podium presentation at the European Society for Medical Oncology Congress 2026. The event will take place in Madrid from October 23rd to 27th.
During the event Agendia will also present two more research posters. These presentations will be based on findings from its ongoing FLEX Study. The company’s key presentation focuses on the development of an AI-powered approach to MammaPrintⓇ. The approach utilizes routine whole slide images of breast cancer tissue.
The research also looks at the role of artificial intelligence in supporting genomic testing. It also covers a strategy for expanding access to sophisticated testing globally. AI-powered digital pathology continues to generate interest throughout healthcare and oncology. Its ability to improve consistency and scalability of pathology workflows is being explored by researchers.
Agendia’s research is specifically on early-stage breast cancer. The company hopes to demonstrate development and validation of its digital pathology approach. The study was presented at ESMO 2026 as a late-breaking abstract. It will be featured in a dedicated session on AI and digital health.
“Germline BRCA1 and BRCA2 mutations are associated with distinct breast cancer phenotypes, but their association with gene expression-based subtypes has not been well-studied. Ki67 is a biomarker whose utility is limited by variability between laboratories and by the lack of consensus on meaningful levels of expression,” said William Audeh, M.D., M.S., Chief Medical Officer at Agendia. “Both studies we are bringing to ESMO 2026 to illustrate how genomic risk classification correlates with these biomarkers in a real-world population. The FLEX Study has allowed questions like these to be answerable through the analysis of large scale real-world evidence, and we look forward to sharing the complete findings in Madrid following their scheduled presentations.”
ESMO 2026 Podium Presentation Details
Agendia will present its research under the title “AI Driven Digital Pathology for the 70 Gene Recurrence Signature: Development and Validation in Early Stage Breast Cancer.” Laura van ‘t Veer, PhD, will lead the podium presentation. She serves as Co-founder and Chief Research Officer at Agendia.
The presentation will take place during the AI and digital health session. The session will provide a platform for discussing emerging healthcare technologies.
This study shows that AI is becoming more important in digital pathology and also shows the larger trends in the field of personalized medicine and genetic diagnostics. Agendia will also be presenting two other posters at the ESMO event. Both posters are based on findings from the active FLEX Study where ample real-life data is used to study breast cancer issues.
These areas include biomarkers, inherited mutations, and genomic tumor biology. The research will also examine connections between genomic risk and Ki67. In addition, another study will assess germline BRCA1 and BRCA2 mutations. Researchers will examine their relationship with gene expression profiling.
FLEX Study Supports Real-World Breast Cancer Research
Further research from Agendia demonstrates the value of large-scale real-world evidence. Evidence of this kind may be useful in the investigation of various breast cancer characteristics. The study will examine genomic risk, as well as key breast cancer biomarkers. It will also look at gene expression based subtypes that are associated with inherited mutations. The studies looked at germline mutations in BRCA1 and BRCA2 . Ki67 is also taken into consideration, and is still an important biomarker in breast cancer research.
But the interpretation of the Ki67 results is still a problem for the researchers. Laboratory variability – Reproducibility can be affected when different testing environments are used. Therefore, the study seeks to contribute more toward the understanding of these relationships. The FLEX Study uses data from a real world population. Agendia expects to report the full results in Madrid following the planned presentations. The firm’s presence at ESMO demonstrates its continued dedication to precision oncology.
Furthermore, the study shows how AI-based digital pathology can be used to support breast cancer research. It also speaks to the increasing convergence of digital health and genomic medicine. Agendia’s ESMO 2026 presentations will feature a number of research spaces. These include artificial intelligence, digital pathology, genomic risk and breast cancer biomarkers.
The company will also showcase how real-world evidence can complement cutting-edge oncology research. Together, these efforts solidify the growing importance of technology in precision medicine.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
